A double-blind controlled trial of ‘Gaviscon’ in patients with symptomatic gastro-oesophageal reflux

Abstract
In a double-blind trial in 26 patients with symptomatic gastro-oesophageal reflux, the alginate I effervescent I antacid compound ‘Gaviscon’ was compared with antacid containing placebo similarly formulated. Retrosternal pain after meals and at night was significantly reduced whilst patients were taking ‘Gaviscon’ and the beneficial effects lasted for many weeks after discontinuation of the active preparation.